A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Chronic Hepatitis C
Interventions
DRUG

Daclatasvir

Oral Solution, Oral, Single Dose

DRUG

Placebo

Oral Solution, Oral, Single Dose

Trial Locations (7)

19107

Thomas Jefferson University, Philadelphia

21225

Parexel International Corporation, Baltimore

22908

University Of Virginia Digestive Health Center Of Excellence, Charlottesville

32809

Orlando Clinical Research Center, Orlando

55905

Mayo Clinic, Rochester

92801

Advanced Clinical Research Institute, Anaheim

08690

Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY